Last reviewed · How we verify
ALK tree AIT 12 DU — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
ALK tree AIT 12 DU (ALK tree AIT 12 DU) — ALK-Abelló A/S. Allergen immunotherapy designed to desensitize the immune system through controlled exposure to specific allergens.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ALK tree AIT 12 DU TARGET | ALK tree AIT 12 DU | ALK-Abelló A/S | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ALK tree AIT 12 DU CI watch — RSS
- ALK tree AIT 12 DU CI watch — Atom
- ALK tree AIT 12 DU CI watch — JSON
- ALK tree AIT 12 DU alone — RSS
Cite this brief
Drug Landscape (2026). ALK tree AIT 12 DU — Competitive Intelligence Brief. https://druglandscape.com/ci/alk-tree-ait-12-du. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing